胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展

doi:10.3969/j.issn.1004-583X.2022.05.018

摘要/Abstract

摘要：

肥胖对公共健康的威胁日益严重,使患者生活质量降低,死亡风险增加。药物治疗可以帮助肥胖患者减轻体重,且有助于降低体重反弹的风险,从而减少肥胖相关并发症。胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RAs)促进胰岛素分泌,并以葡萄糖依赖的方式减少了胰高血糖素的分泌,使胃排空延迟、肠道运动性降低,并且可以激活下丘脑的神经通路和食欲调节区域,使食欲下降、食物摄入减少,从而治疗肥胖。本研究通过对GLP-1RAs治疗肥胖的机制、临床试验、安全性和耐受性、主要不良反应、禁忌证及优势等进行综述,旨在为肥胖的治疗提供理论依据。

中图分类号:

R589.25

杨静静, 黄帅, 吴倩, 赵丽丽, 蒋影. 胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展[J]. 临床荟萃, 2022, 37(5): 477-480.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2022.05.018

https://www.lchc.cn/CN/Y2022/V37/I5/477

参考文献 31

[1]	Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(7):446-461. doi: 10.1016/S2213-8587(21)00118-2 URL
[2]	杨飞, 肖纯. 高血压肥胖者血浆促动脉硬化指数与心血管疾病风险的相关性研究[J]. 河北医科大学学报, 2020, 41(2): 138-141.
[3]	Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5[J]. Obesity (Silver Spring), 2020, 28(6):1050-1061. doi: 10.1002/oby.22794 URL
[4]	丁敏, 李春君, 邢云芝, 等. GLP-1Ra减少高糖诱导的β细胞凋亡作用机制探讨[J]. 天津医药, 2015, 43(11): 1217-1221,1345.
[5]	管子函, 张炳才, 郑乐群. 胰高血糖素样肽-1类似物联合二甲双胍对肥胖2型糖尿病患者血糖及胰岛素抵抗的影响[J]. 中华内分泌外科杂志, 2019, 13(2): 144-149.
[6]	Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial[J]. Diabetologia, 2016, 59(5):954-965. doi: 10.1007/s00125-016-3874-y URL
[7]	Bae JH, Choi HJ, Cho KIK, et al. Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus[J]. Diabetes Metab J, 2020, 44(2):248-259. doi: 10.4093/dmj.2019.0018 URL
[8]	Coveleskie K, Kilpatrick LA, Gupta A, et al. The effect of the GLP-1 analogue exenatide on functional connectivity within an NTS-based network in women with and without obesity[J]. Obes Sci Pract, 2017, 3(4):434-445. doi: 10.1002/osp4.124 pmid: 29259802
[9]	Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss[J]. J Clin Invest, 2014, 124(10):4473-4488. doi: 10.1172/JCI75276 pmid: 25202980
[10]	Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinolog, 2014, 155 (4):1280-1290. doi: 10.1210/en.2013-1934 URL
[11]	Holt MK, Pomeranz LE, Beier KT, et al. Synaptic inputs to the mouse dorsal vagal complex and its resident preproglucagon neurons[J]. J Neurosci, 2019, 39(49):9767-9781. doi: 10.1523/JNEUROSCI.2145-19.2019 URL
[12]	Al Helaili A, Park SJ, Beyak MJ. Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents[J]. Biochem Biophys Res Commun, 2020, 533(1): 110-117. doi: 10.1016/j.bbrc.2020.08.045 URL
[13]	Gilijamse PW, Demirkiran A, van Wagensveld BA, et al. The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class Ⅱ/Ⅲ obesity[J]. Surg Obes Relat Dis, 2021, 17(8):1440-1448. doi: 10.1016/j.soard.2021.04.022 pmid: 34083134
[14]	Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity[J]. Diabetes Obes Metab, 2018, 20(3):610-619. doi: 10.1111/dom.13120 pmid: 28941314
[15]	Bergmann NC, Lund A, Gasbjerg LS, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: A randomised, crossover study[J]. Diabetologia, 2019, 62(4):665-675. doi: 10.1007/s00125-018-4810-0 pmid: 30683945
[16]	van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults[J]. Int J Obes (Lond), 2014, 38(6):784-793. doi: 10.1038/ijo.2013.162 URL
[17]	Kadouh H, Chedid V, Halawi H, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity[J]. J Clin Endocrinol Metab, 2020, 105(5):1552-1563. doi: 10.1210/clinem/dgz140 URL
[18]	Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating and gastric emptying in subjects with obesity[J]. Diabetes Obes Metab, 2020, 23(3):754-762. doi: 10.1111/dom.14280 URL
[19]	Pratley RE, Kang J, Trautmann ME, et al. Body weight management and safety with efpeglenatide in adults without diabetes: A phase Ⅱ randomized study[J]. Diabetes Obes Metab, 2019, 21(11):2429-2439. doi: 10.1111/dom.13824 URL
[20]	Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity[J]. N Engl J Med, 2020, 382(22):2117-2128. doi: 10.1056/NEJMoa1916038 URL
[21]	Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management[J]. N Engl J Med, 2015, 373(1):11-22. doi: 10.1056/NEJMoa1411892 URL
[22]	Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity[J]. N Engl J Med, 2021, 384(11):989-1002. doi: 10.1056/NEJMoa2032183 URL
[23]	Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The scale insulin randomized controlled trial[J]. Diabetes Care, 2020, 43(5):1085-1093. doi: 10.2337/dc19-1745 URL
[24]	Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial[J]. Obesity (Silver Spring), 2020, 28(3):529-536. doi: 10.1002/oby.22726 URL
[25]	Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults[J]. Int J Obes (Lond), 2014, 38(5):689-697. doi: 10.1038/ijo.2013.149 URL
[26]	O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial[J]. Lancet, 2018, 392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2 URL
[27]	Horowitz M, Aroda VR, Han J, et al. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences[J]. Diabetes Obes Metab. 2016, 19(5):672-681. doi: 10.1111/dom.12872 URL
[28]	Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss:The SCALE Maintenance randomized study[J]. Int J Obes (Lond), 2013, 37(11):1443-1451. doi: 10.1038/ijo.2013.120 URL
[29]	Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide[J]. Int J Obes (Lond), 2012, 36(6):843-854. doi: 10.1038/ijo.2011.158 URL
[30]	Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity[J]. Diabetes Obes Metab, 2017, 19(9):1242-1251. doi: 10.1111/dom.12932 pmid: 28266779
[31]	罗琼, 徐文光, 李琴, 等. GLP-1RA、DPP-4抑制剂治疗2型糖尿病肥胖患者的疗效及其对心血管疾病发病风险的对比[J]. 心血管康复医学杂志, 2021, 30(2): 159-164.

胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏淼, 王飒爽, 赵东强. 《中国肥胖症消化内镜治疗专家共识》解读[J]. 临床荟萃, 2025, 40(4): 366-371.
[2]	延天美, 吴亚楠, 梁鹏, 魏立民. 粪便微生物移植:肥胖患者减重的新方案[J]. 临床荟萃, 2024, 39(5): 455-459.
[3]	江黎晨, 章秋, 胡红琳. Apelin在多囊卵巢综合征中的研究进展[J]. 临床荟萃, 2023, 38(3): 285-288.
[4]	任玉梅, 章秋, 胡红琳. 多囊卵巢综合征患者血清S100A4水平变化及其对多囊卵巢综合征的影响[J]. 临床荟萃, 2023, 38(12): 1078-1085.
[5]	赵丽岩, 康玮, 王庆周, 李博鹏, 曹亚薇, 李俊粉, 邵亮, 王康. 脂质蓄积指数、内脏脂肪指数对2型糖尿病患者一级亲属糖代谢的影响[J]. 临床荟萃, 2022, 37(9): 804-807.
[6]	贾卓雅, 陈晓依, 陈树春. 胰高糖素样肽-1受体激动剂改善肥胖致雄性生殖功能下降的作用机制[J]. 临床荟萃, 2022, 37(7): 658-662.
[7]	龚琳捷, 张松. 低碳生酮饮食干预2型糖尿病的研究进展[J]. 临床荟萃, 2021, 36(7): 651-654.
[8]	李蕾, 阿勒滕齐齐格, 张明琛, 蒋升. 胰高血糖素样肽-1受体激动剂治疗多囊卵巢综合征患者有效性与安全性的Meta分析[J]. 临床荟萃, 2021, 36(5): 395-401.
[9]	李超1，宋文惠2. 肥胖症儿童临床相关因素[J]. 临床荟萃, 2020, 35(2): 177-180.
[10]	郭蕊1, 韦祁山2，李雯彬3，朱慧1，于国伟1. 短链脂肪酸通过肠脑轴改善肥胖的研究进展[J]. 临床荟萃, 2019, 34(12): 1148-1152.
[11]	邱轩，徐晓蒙，刘宽芝. 关于肥胖，你知道多少？[J]. 临床荟萃, 2017, 32(9): 812-812.
[12]	王晓琳, 谢颖, 杜红珍, 李增宁. 中国女性脑卒中发病危险因素的Meta分析[J]. 临床荟萃, 2016, 31(4): 418-422.
[13]	彭阳, 王战建. 肥胖相关慢性炎症与2型糖尿病[J]. 临床荟萃, 2016, 31(4): 458-461.
[14]	王绵,张力辉,苏胜偶. 2015年内分泌代谢疾病主要进展[J]. 临床荟萃, 2016, 31(2): 162-167.
[15]	王绵;张力辉;苏胜偶. 2014内分泌代谢疾病临床进展[J]. 临床荟萃, 2015, 30(2): 150-156.